Tumoricidal activity of low-energy 160-KV versus 6-MV X-rays against platinum-sensitized F98 glioma cells

A Nanomedicine Structure-Activity Framework for Research, Development, and Regulation of Future Cancer Therapies

Despite their clinical success in drug delivery applications, the potential of theranostic nanomedicines is hampered by mechanistic uncertainty and a lack of science-informed regulatory guidance. Both the therapeutic efficacy and the toxicity of nanoformulations are tightly controlled by the complex interplay of the nanoparticle's physicochemical properties and the individual patient/tumor biology; however, it can be difficult to correlate such information with observed outcomes. Additionally, as nanomedicine research attempts to gradually move away from large-scale animal testing, the need for computer-assisted solutions for evaluation will increase. Such models will depend on a clear understanding of structure-activity relationships. This review provides a comprehensive overview of the field of cancer nanomedicine and provides a knowledge framework and foundational interaction maps that can facilitate future research, assessments, and regulation. By forming three complementary maps profiling nanobio interactions and pathways at different levels of biological complexity, a clear picture of a nanoparticle's journey through the body and the therapeutic and adverse consequences of each potential interaction are presented.

The radioenhancement potential of Schiff base derived copper (II) compounds against lung carcinoma in vitro

For the last years, copper complexes have been intensively implicated in biomedical research as components of cancer treatment. Herewith, we provide highlights of the synthesis, physical measurements, structural characterization of the newly developed Cu(II) chelates of Schiff Bases, Cu(Picolinyl-L-Tryptopahanate)2, Cu(Picolinyl-L-Tyrosinate)2, Cu(Isonicotinyl-L-Tyrosinate)2, Cu(Picolinyl-L-Phenylalaninate)2, Cu(Nicotinyl-L-Phenylalaninate)2, Cu(Isonicotinyl-L-Phenylalaninate)2, and their radioenhancement capacity at kV and MV ranges of irradiation of human lung carcinoma epithelial cells in vitro. The methods of cell growth, viability and proliferation were used. All compounds exerted very potent radioenhancer capacities in the irradiated lung carcinoma cells at both kV and MV ranges in a 100 μM concentration. At a concentration of 10 μM, only Cu(Picolinyl-L-Tyrosinate)2, Cu(Isonicotinyl-L-Tyrosinate)2, Cu(Picolinyl-L-Phenylalaninate)2 possessed radioenhancer properties at kV and MV ranges. Cu(Picolinyl-L-Tryptophanate)2 showed radioenhancer properties only at kV range. Cu(Nicotinyl-L-Phenylalaninate)2 and Cu(Isonicotinyl-L-Phenylalaninate)2 showed remarkable radioenhancer activity only at MV range. All compounds acted in dose-dependent manner at both tested energy ranges. These copper (II) compounds, in combination with 1 Gy irradiation at either 120 kV or 6 MV, are more efficient at delaying cell growth of lung cancer cells and at reducing cell viability in vitro than the irradiation administered alone. Thus, we have demonstrated that the studied copper compounds have a good potential for radioenhancement.

Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment

Colon cancer is an adenocarcinoma, which subsequently develops into malignant tumors, if not treated properly. The current colon cancer therapy mainly revolves around chemotherapy, radiotherapy and surgery, but the search continues for more effective interventions. With the advancement of nanoparticles (NPs), it is now possible to diagnose and treat colon cancers with different types, shapes, and sizes of NPs. Nanoformulations such as quantum dots, iron oxide, polymeric NPs, dendrimers, polypeptides, gold NPs, silver NPs, platinum NPs, and cerium oxide have been either extensively used alone or in combination with other nanomaterials or drugs in colon cancer diagnosis, and treatments. These nanoformulations possess high biocompatibility and bioavailability, which makes them the most suitable candidates for cancer treatment. The size and shape of NPs are critical to achieving an effective drug delivery in cancer treatment and diagnosis. Most NPs currently are under different testing phases (in vitro, preclinical, and clinical), whereas some of them have been approved for therapeutic applications. We have comprehensively reviewed the recent advances in the applications of NPs-based formulations in colon cancer diagnosis and treatment.

Database NORAD-Atomic-Data for Atomic Processes in Plasma

The online atomic database of NORAD-Atomic-Data, where NORAD stands for Nahar OSU Radiative, is part of the data sources of the two international collaborations of the Opacity Project (OP) and the Iron Project (IP). It contains large sets of parameters for the dominant atomic processes in astrophysical plasmas, such as, (i) photo-excitation, (ii) photoionization, (iii) electron–ion recombination, (iv) electron–impact excitations. The atomic parameters correspond to tables of energy levels, level-specific total photoionization cross-sections, partial photoionization cross-sections of all bound states for leaving the residual ion in the ground state, partial cross-sections of the ground state for leaving the ion in various excited states, total level-specific electron–ion recombination rate coefficients that include both the radiative and dielectronic recombination, total recombination rate coefficients summed from contributions of an infinite number of recombined states, total photo-recombination cross-sections and rates with respect to photoelectron energy, transition probabilities, lifetimes, collision strengths. The database was created after the first two atomic databases, TOPbase under the OP and TIPbase under the IP. Hence the contents of NORAD-Atomic-Data are either new or from repeated calculations using a much larger wave function expansion making the data more complete. The results have been obtained from the R-matrix method using the close-coupling approximation developed under the OP and IP, and from atomic structure calculations using the program SUPERSTRUCTURE. They have been compared with available published results which have been obtained theoretically and experimentally, and are expected to be of high accuracy in general. All computations were carried out using the computational facilities at the Ohio Supercomputer Center (OSC) starting in 1990. At present it contains atomic data for 154 atomic species, 98 of which are lighter atomic species with nuclear charge Z ≤ 28 and 56 are heavier ones with Z > 28. New data are added with publications.

Megavoltage Radiosensitization of Gold Nanoparticles on a Glioblastoma Cancer Cell Line Using a Clinical Platform

Gold nanoparticles (GNPs) have demonstrated significant dose enhancement with kilovoltage (kV) X-rays; however, recent studies have shown inconsistent findings with megavoltage (MV) X-rays. We propose to evaluate the radiosensitization effect on U87 glioblastoma (GBM) cells in the presence of 42 nm GNPs and irradiated with a clinical 6 MV photon beam. Cytotoxicity and radiosensitization were measured using MTS and clonogenic cellular radiation sensitivity assays, respectively. The sensitization enhancement ratio was calculated for 2 Gy (SER_2Gy) with GNP (100 μg/mL). Dark field and MTS assays revealed high co-localization and good biocompatibility of the GNPs with GBM cells. A significant sensitization enhancement of 1.45 (p = 0.001) was observed with GNP 100 μg/mL. Similarly, at 6 Gy, there was significant difference in the survival fraction between the GBM alone group (mean (M) = 0.26, standard deviation (SD) = 0.008) and the GBM plus GNP group (M = 0.07, SD = 0.05, p = 0.03). GNPs enabled radiosensitization in U87 GBM cells at 2 Gy when irradiated using a clinical platform. In addition to the potential clinical utility of GNPs, these studies demonstrate the effectiveness of a robust and easy to standardize an in-vitro model that can be employed for future studies involving metal nanoparticle plus irradiation.

Broadband, monochromatic and quasi-monochromatic x-ray propagation in multi-Z media for imaging and diagnostics

With the advent of monochromatic and quasi-monochromatic x-ray sources, we explore their potential with computational and experimental studies on propagation through a combination of low and high-Z (atomic number) media for applications to imaging and detection. The multi-purpose code GEANT4 and a new code PHOTX are employed in numerical simulations, and a variety of x-ray sources are considered: conventional broadband devices with well-known spectra, quasi-monochromatic laser driven sources, and monochromatic synchrotron x-rays. Phantom samples consisting of layers of low-Z and high-Z material are utilized, with atomic-molecular species ranging from H₂O to gold. Differential and total attenuation of x-ray fluxes from the different x-ray sources are illustrated through simulated x-ray images. Main conclusions of this study are: I. It is shown that a 65 keV Gaussian quasi-monochromatic source is capable of better contrast with less radiation exposure than a common 120 kV broadband simulator. II. A quantitative measure is defined and computed as a metric to compare the efficacy of any two x-ray sources, as a function of concentration of high-Z moieties in predominantly low-Z environment and depth of penetration. III. Characteristic spectral features of [Formula: see text], [Formula: see text] fluorescent emission and Compton scattering indicate pathways for accelerating x-ray photoexcitation and absorption; in particular, we model the tungsten [Formula: see text] at 59 keV alongside experimental measurements at the European synchrotron research facility to search for the signature of induced [Formula: see text] resonance fluorescence. The present study should contribute to the understanding of diagnostic potential of new x-ray sources under development, as well as the underlying fundamental physical processes and features for biomedical applications.

Study of the biochemical effects induced by X-ray irradiations in combination with gadolinium nanoparticles in F98 glioma cells: first FTIR studies at the Emira laboratory of the SESAME synchrotron

One strategy to improve the clinical outcome of radiotherapy is to use nanoparticles as radiosensitizers.